Adding evolocumab to usual lipid-lowering care for acute pancreatitis caused by very high triglycerides
Official title: Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis: A Pilot Randomised Controlled Trial
Run by General Hospital of Shenyang Military Region · NCT07388420 · Data updated 2026-11-12
This study will try adding evolocumab to standard lipid-lowering care for adults hospitalized with hypertriglyceridemia-induced acute pancreatitis to see if it lowers triglycerides faster and reaches target levels within a week.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | General Hospital of Shenyang Military Region Academic / other |
| Drugs / interventions | evolocumab |
| Locations | 1 site (Shenyang, Liaoning) |
| Status | Recruiting |
| Started | January 2, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | September 25, 2026 |
| Trial ID | NCT07388420 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with hypertriglyceridemia-induced acute pancreatitis and mixed hyperlipidemia who can give informed consent and have not recently received lipid-lowering drugs or blood purification are ideal candidates.
✕Probably not a fit
Patients who recently received lipid-lowering therapy or blood purification, those who used evolocumab within one month, pregnant or breastfeeding individuals, people with serious life-limiting comorbidities, or those with multiple drug/food allergies may not receive benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, controlled trial will enroll 40 patients with hypertriglyceridemia-induced acute pancreatitis and randomly assign them 1:1 to conventional lipid-lowering therapy with or without added evolocumab. The primary endpoints are serum triglyceride levels at days 3 and 7 and the proportions of patients reaching triglyceride thresholds of <5.65 mmol/L and <1.7 mmol/L at those time points. Secondary endpoints include other lipid measures (TC, HDL, LDL, lipoprotein(a)) at days 3 and 7, incidence of recurrent or severe acute pancreatitis and other complications, length of hospital stay, and total hospitalization costs. Treatment is provided in the inpatient setting at participating hospital site(s).
Why it matters
Potential benefit: If successful, adding evolocumab could produce faster triglyceride reduction, which may lower the risk of severe pancreatitis and shorten hospital stays.
How similar studies have gone: PCSK9 inhibitors such as evolocumab are well established for lowering LDL and can modestly reduce triglycerides, but randomized evidence specifically testing their use in hypertriglyceridemia-induced acute pancreatitis is limited, so this application is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18\~75 years * Patients with HTG-AP * Mixed hyperlipidemia * Sign the informed consent form Exclusion Criteria: * Patients who have received lipid-lowering drugs or blood purification treatment within one week before enrollment * Patients who have used evolocumab within one month before enrollment * Patients who are accompanied by diseases that can seriously affect the survival * Patients who have participated in the clinical research of other drugs within one month * Patients who are pregnant or breastfeeding * Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies * Other circumstances that researchers consider not suitable for participation in this study
Where it's running
-
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
Shenyang, Liaoning, China Recruiting
Study contacts
- Study coordinator: Xingshun Qi
- Email: xingshunqi@126.com
- Phone: 18909881019
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Early LDL-C lowering with evolocumab after ACS to see if it slows plaque progression
This trial tests whether starting evolocumab soon after a heart attack or unstable angina, in addition to standard therapy, reduces non-culprit plaque growth over a year.
-
Long-term use of inclisiran, evolocumab, and alirocumab in real-world care
This study tests whether people with high cholesterol medications stick with their PCSK9 inhibitors and inclisiran over the long term in everyday clinical practice.
-
Intelligent lipid-management system to help stroke or TIA patients on evolocumab reach one-year LDL-C targets
We will test whether an intelligent lipid-management decision-support system helps adults in China with ischemic stroke or TIA who are taking evolocumab reach LDL-C under 1.8 mmol/L after one year.
-
Evaluating the effects of obicetrapib and evolocumab on Lp(a) levels
This study is testing if a new medication called obicetrapib, alone and with another drug called evolocumab, can lower Lp(a) levels in people who have high Lp(a).
-
Bacillus subtilis and Enterococcus faecium Probiotic Plus Lipid-Lowering Therapy for HTG-AP
This trial tests whether adding a probiotic capsule to standard lipid-lowering therapy helps people with mild HTG-AP see lower triglycerides and better recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.